Apple TV dropped the first real trailer for Neuromancer at San Diego Comic-Con over the weekend, and tech Twitter has been talking about brain implants ever since. The 10-episode series, premiering January 22, 2027, adapts William Gibson's 1984 novel that essentially invented the cyberpunk genre. Its story of hackers who jack directly into cyberspace through neural ports, and assassins with mirrored eyes and embedded blades, has never been adapted for screens. That it's arriving now, as companies like Neuralink push brain-computer interfaces toward clinical scale, feels significant.
The trailer stars Callum Turner as Case, a "damaged, top-rung super-hacker," alongside Briana Middleton as Molly, a razor-girl assassin. Mark Strong, Peter Sarsgaard, and Clémence Poésy round out the ensemble. Gibson himself is an executive producer. The visual identity leans into cyberpunk's expected neon and grime, though with more sunlight than the genre typically allows.
See you on the other side, cowboy.#Neuromancer — January 22 pic.twitter.com/btlZ48m48I
— Apple TV (@AppleTV) July 25, 2026
The Infection Question
Within hours of the trailer's release, the conversation had shifted from the show itself to the technology it depicts. The core question: Can permanent human implants ever scale without becoming infection vectors?
Palmer Luckey, the Oculus VR founder and current Anduril Industries CEO, weighed in almost immediately. "Look up the Oticon Ponto," Luckey wrote. "You can coat biocompatible titanium with proteins that make your body treat it like a tooth."
Look up the Oticon Ponto. You can coat bicompatible titanium with proteins that make your body treat it like a tooth. pic.twitter.com/K3djXn1Fhn
— Palmer Luckey (@PalmerLuckey) July 27, 2026
He's referencing a technology that's been on the market for over a decade. The Oticon Ponto system is a bone-anchored hearing device that uses a small titanium implant surgically placed behind the ear. The implant relies on a process called osseointegration, where living bone grows directly into the grooves of the titanium surface without scar tissue formation. The bone treats the implant as an extension of itself.
Research has explored coating titanium implants with proteins like fibronectin to accelerate this integration. One study found that protein-coated titanium implants increased mechanical fixation threefold compared to uncoated versions. The principle is straightforward: trick the body into treating foreign metal as native tissue.
The Neuralink Factor
Neuralink has taken notice. The company's latest surgical robot can insert electrode threads through the dura mater without removing it, which reduces infection risk and allows patients to recover in days rather than weeks. According to company data, 21 patients have received implants across four countries with zero serious device-related adverse events reported.
Elon Musk announced late last year that Neuralink would begin high-volume production in 2026. The company's stated goal is to expand from dozens of implanted patients to several hundred this year. Whether the manufacturing and surgical automation can scale that aggressively remains an open question.
Competitors are approaching the problem differently. Synchron's Stentrode reaches the brain through blood vessels, avoiding open brain surgery entirely, though it provides lower-resolution signals. Paradromics argues that Neuralink's reliance on a proprietary surgical robot could itself hamper scalability.
Why Now
The demand side of the equation is shifting. The global neurotechnology market is projected to exceed $20 billion by 2028. Much of that growth is driven by therapeutic applications: restoring communication for patients with paralysis, treating neurological disorders, controlling advanced prosthetics. But the consumer use case hovers at the edge of every conversation.
As AI capabilities accelerate, the interface bottleneck becomes more apparent. Typing is slow. Voice is awkward. The appeal of thought-to-action communication is obvious, especially as AI models become capable enough that the limiting factor is how quickly humans can express intent.
Gibson wrote Neuromancer when the internet barely existed. The book imagined cyberspace as a consensual hallucination navigated through direct neural connection. Forty-two years later, the trailer for its adaptation arrives as companies work to make that hallucination tangible. The gap between science fiction and surgical reality is narrowing.
Apple's series premieres January 22, with two episodes dropping that day and new episodes weekly through March 19.
